Cancer News and Research

Latest Cancer News and Research

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

Akela Pharma, Inc., a leader in the development of therapeutics for the treatment of pain, and the company's wholly owned subsidiary, PharmaForm, today announced its financial results for the three and six months ended June 30, 2010.

13 Aug 2010

Study finds Olaparib can reduce tumor size in ovarian cancer women

Understanding the underlying genetic weakness of certain types of cancer may lead to targeted therapy and provide the key to effective treatment, a new study suggests. An international consortium of researchers has shown that an investigational drug, Olaparib, can reduce the size of tumors in women with advanced hereditary ovarian cancer with BRCA gene mutations.

13 Aug 2010

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Cancer Research Technology has signed a deal to provide biotech company ValiRx plc with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.The compound, now called VAL 201, has been shown in pre-clinical tests in mice to stop growth of tumours which have been unresponsive to hormone treatments. VAL 201 blocks genes which can cause prostate cancer to develop. The compound has been shown to be effective in treating mice with breast and prostate cancer and is now rapidly progressing towards the first clinical trials in patients.

13 Aug 2010

Tracking heart rate can provide important marker of health issues: Research

An elevated resting heart rate that develops or persists during follow-up is associated with a significantly increased risk of death, whether from heart disease or other causes, researchers from the Ronald O. Perelman Heart Institute at NewYork-Presbyterian Hospital/Weill Cornell Medical Center found studying outcomes in more than 9,000 patients.

13 Aug 2010

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

13 Aug 2010

RPA70 associated with SUMO-specific protease facilitates DNA repair: Research

A team of investigators led by a physician-scientist at The University of Texas MD Anderson Cancer Center has shown for the first time that the small protein SUMO can team up with the replication protein A (RPA) complex to facilitate DNA repair. The study is published in the Aug. 13 edition of the journal Molecular Cell.

13 Aug 2010

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.

13 Aug 2010

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, and the Multiple Myeloma Research Consortium announced today the initiation of a Phase II clinical trial of the cyclin-dependent kinase inhibitor, AT7519, to treat patients with relapsed or refractory multiple myeloma, an incurable blood cancer. The trial is designed to investigate both single agent and combination activity of AT7519 with bortezomib (Velcade®).

13 Aug 2010

Alliance HealthCare Services receives Exceeding Patient Expectations Award for 2009

Alliance HealthCare Services, Inc., a leading national provider of outpatient diagnostic imaging and radiation therapy services, has been awarded the prestigious Exceeding Expectations Award for 2009 by Avatar International, an industry leader in healthcare quality improvement services. Alliance also earned the award in 2007 and 2008.

13 Aug 2010

Merlin protein controls adult cell activity to cause liver cancer

A protein known to be involved in a rare hereditary cancer syndrome may have a role in the regulation of liver stem cells and the development of liver cancer. In the August 15 issue of Genes & Development, a Massachusetts General Hospital (MGH) research team describes finding that the protein called merlin, encoded by the NF2 (neurofibromatosis type 2) gene, controls the activity of adult stem cells that give rise to the two major types of liver cells.

13 Aug 2010

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

Dr. Jean-Philippe Gratton, Director of the Endothelial cell biology research unit at the Institut de recherches cliniques de Montr-al (IRCM), identifies a new intracellular mechanism responsible for modulating vascular permeability: the nitrosylation of beta-catenin protein by nitric oxide. This scientific breakthrough could have a possible impact on the treatment of cancerous tumours by altering the permeability of the blood vessels irrigating them. Dr. Gratton's team will publish the results of its research tomorrow in the scientific journal Molecular Cell.

13 Aug 2010

American Society of Hematology offers recommendations to propel collaborative research in regenerative medicine

The American Society of Hematology has developed specific recommendations to the scientific community and federal agencies to help propel collaborative research in regenerative medicine in order to make real strides in improving patient care. These recommendations were released today in Blood, ASH's premier scientific journal, in the article titled "Enhancing Research in Regenerative Medicine."

13 Aug 2010

Transgenomic second-quarter net loss increases to $1.1 million

Transgenomic, Inc. today reported financial results for the three and six months ended June 30, 2010, and provided a business update.

13 Aug 2010

Arrowhead third-quarter 2010 net loss decreases to $0.4 million

Arrowhead Research Corporation today announced financial results for its fiscal 2010 third quarter ended June 30, 2010.

13 Aug 2010

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

Fenwal Inc., a global medical technology company focused on improving blood collection, separation, safety and availability, announced today that the U.S. Food and Drug Administration has granted Fenwal a new 510(k) clearance for its Amicus® blood cell separator.

13 Aug 2010

PDL BioPharma retires $61.7 million of 2.75% Convertible Subordinated Notes due 2023

PDL BioPharma, Inc. announced today that it has completed the retirement of $61.7 million in aggregate principal amount of the Company's outstanding 2.75% Convertible Subordinated Notes, due August 16, 2023 for consideration consisting of the issuance of 11.1 million shares of the Company's common stock.

12 Aug 2010

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Genta Incorporated today announced financial results for the quarter ending June 30, 2010.

12 Aug 2010

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today reported financial and operating results for the second quarter ended June 30, 2010.

12 Aug 2010

Gentium second-quarter total revenues increase to EUR 7.55 million

Gentium S.p.A. today reported financial results for the first half of 2010 and for the quarter ended June 30, 2010. The Company reports its financial condition and operating results using U.S. Generally Accepted Accounting Principles (GAAP). The Company's financial statements are prepared using the Euro as its functional currency.

12 Aug 2010

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Amorfix Life Sciences, a product development company focused on misfolded protein diseases, today announced its operational and financial results for the three months ended June 30, 2010.

12 Aug 2010

Cancer News and Research

Latest Cancer News and Research

Akela reports $0.1M net income for second-quarter 2010 vs. $1.1M net loss for same period in 2009

Study finds Olaparib can reduce tumor size in ovarian cancer women

Cancer Research Technology grants Valirx global rights to develop VAL 201 for cancer treatment

Tracking heart rate can provide important marker of health issues: Research

OXiGENE reports $2.5M net income for second-quarter 2010 vs. $5.3M net loss for same period in 2009

RPA70 associated with SUMO-specific protease facilitates DNA repair: Research

Problems with analytical study design and data misinterpretation leads to biomarker failure: Report

Astex and MMRC commence Phase II clinical trial of AT7519 CDK inhibitor in multiple myeloma

Alliance HealthCare Services receives Exceeding Patient Expectations Award for 2009

Merlin protein controls adult cell activity to cause liver cancer

Research identifies intracellular mechanism for altering blood vessels permeability for tumours treatment

American Society of Hematology offers recommendations to propel collaborative research in regenerative medicine

Transgenomic second-quarter net loss increases to $1.1 million

Arrowhead third-quarter 2010 net loss decreases to $0.4 million

FDA grants new 510(k) clearance for Fenwal's Amicus blood cell separator

PDL BioPharma retires $61.7 million of 2.75% Convertible Subordinated Notes due 2023

Genta reports second-quarter net income of $25.4M against net loss of $43.1M in 2009

Aeterna Zentaris second-quarter revenues decrease to $5.6 million

Gentium second-quarter total revenues increase to EUR 7.55 million

Amorfix first-quarter fiscal 2011 net loss from operations increases to $1,724,745

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook - Oncology (1st Edition) eBook

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in